Characterization of major phytocannabinoids, cannabidiol and cannabinol, as isoform-selective and potent inhibitors of human CYP1 enzymes

Biochemical Pharmacology

Volumn 79, Issue 11, 2010, Pages 1691-1698

  Yamaori, Satoshi ^a   Kushihara, Mika ^a   Yamamoto, Ikuo ^b   Watanabe, Kazuhito ^a  

^a HOKURIKU UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY OF HEALTH AND WELFARE   (Japan)

Author keywords

Cannabidiol; Cannabinol; CYP1; Inhibition; Mechanism based inactivation

Indexed keywords

CANNABIDIOL; CANNABINOL; CYTOCHROME P450; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 1B1; DRONABINOL; ETHOXYRESORUFIN DEETHYLASE;

ANIMAL CELL; ARTICLE; DRUG EFFICACY; DRUG POTENCY; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INACTIVATION; ENZYME INHIBITION; HUMAN; KINETICS; LIVER MICROSOME; NONHUMAN; PRIORITY JOURNAL;

ARYL HYDROCARBON HYDROXYLASES; CANNABIDIOL; CANNABINOIDS; CANNABINOL; CATALYSIS; CYTOCHROME P-450 CYP1A1; CYTOCHROME P-450 CYP1A2; HUMANS; MICROSOMES, LIVER; PROTEIN ISOFORMS;

EID: 77950094856     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2010.01.028     Document Type: Article

References (54)

1. ElSohly M.A., Slade D. Chemical constituents of marijuana: the complex mixture of natural cannabinoids. Life Sci 2005, 78:539-548.
2. 9-tetrahydrocannabivarin. Br J Pharmacol 2008, 153:199-215.
3. Paton W.D., Pertwee R.G. Effect of cannabis and certain of its constituents on pentobarbitone sleeping time and phenazone metabolism. Br J Pharmacol 1972, 44:250-261.
4. Consroe P., Wolkin A. Cannabidiol-antiepileptic drug comparisons and interactions in experimentally induced seizures in rats. J Pharmacol Exp Ther 1977, 201:26-32.
5. 9-tetrahydrocannabinol, cannabidiol and cannabinol. Handb Exp Pharmacol 2005, 168:657-690.
6. Watanabe K., Yamaori S., Funahashi T., Kimura T., Yamamoto I. 8-Hydroxycannabinol: a new metabolite of cannabinol formed by human hepatic microsomes. Forensic Toxicol 2006, 24:80-82.
7. Watanabe K., Yamaori S., Funahashi T., Kimura T., Yamamoto I. Cytochrome P450 enzymes involved in the metabolism of tetrahydrocannabinols and cannabinol by human hepatic microsomes. Life Sci 2007, 80:1415-1419.
8. Yamamoto I., Watanabe K., Narimatsu S., Yoshimura H. Recent advances in the metabolism of cannabinoids. Int J Biochem Cell Biol 1995, 27:741-746.
9. Bornheim L.M., Correia M.A. Purification and characterization of the major hepatic cannabinoid hydroxylase in the mouse: a possible member of the cytochrome P-450IIC subfamily. Mol Pharmacol 1991, 40:228-234.
10. 1-tetrahydrocannabinol. Drug Metab Dispos 1992, 20:241-246.
11. Watanabe K., Matsunaga T., Yamamoto I., Funae Y., Yoshimura H. Involvement of CYP2C in the metabolism of cannabinoids by human hepatic microsomes from an old woman. Biol Pharm Bull 1995, 18:1138-1141.
12. Benowitz N.L., Nguyen T.L., Jones R.T., Herning R.I., Bachman J. Metabolic and psychophysiologic studies of cannabidiol-hexobarbital interaction. Clin Pharmacol Ther 1980, 28:115-120.
13. Jaeger W., Benet L.Z., Bornheim L.M. Inhibition of cyclosporine and tetrahydrocannabinol metabolism by cannabidiol in mouse and human microsomes. Xenobiotica 1996, 26:275-284.
14. 9-tetrahydrocannabinol. Am J Respir Cell Mol Biol 2001, 24:339-344.
15. 8-tetrahydrocannabinol-11-oic acid. Biochem Pharmacol 1991, 42:1255-1259.
16. 8-tetrahydrocannabinol in human liver microsomes. Drug Metab Dispos 2000, 28:1291-1296.
17. Wrighton S.A., Campanile C., Thomas P.E., Maines S.L., Watkins P.B., Parker G., et al. Identification of a human liver cytochrome P-450 homologous to the major isosafrole-inducible cytochrome P-450 in the rat. Mol Pharmacol 1986, 29:405-410.
18. Shimada T., Yun C.H., Yamazaki H., Gautier J.C., Beaune P.H., Guengerich F.P. Characterization of human lung microsomal cytochrome P-450 1A1 and its role in the oxidation of chemical carcinogens. Mol Pharmacol 1992, 41:856-864.
19. Shimada T., Hayes C.L., Yamazaki H., Amin S., Hecht S.S., Guengerich F.P., et al. Activation of chemically diverse procarcinogens by human cytochrome P-450 1B1. Cancer Res 1996, 56:2979-2984.
20. Willey J.C., Coy E.L., Frampton M.W., Torres A., Apostolakos M.J., Hoehn G., et al. Quantitative RT-PCR measurement of cytochromes p450 1A1, 1B1, and 2B7, microsomal epoxide hydrolase, and NADPH oxidoreductase expression in lung cells of smokers and nonsmokers. Am J Respir Cell Mol Biol 1997, 17:114-124.
21. Kim J.H., Sherman M.E., Curriero F.C., Guengerich F.P., Strickland P.T., Sutter T.R. Expression of cytochromes P450 1A1 and 1B1 in human lung from smokers, non-smokers, and ex-smokers. Toxicol Appl Pharmacol 2004, 199:210-219.
22. Shimada T., Yamazaki H., Mimura M., Inui Y., Guengerich F.P. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994, 270:414-423.
23. Sutter T.R., Tang Y.M., Hayes C.L., Wo Y.Y., Jabs E.W., Li X., et al. Complete cDNA sequence of a human dioxin-inducible mRNA identifies a new gene subfamily of cytochrome P450 that maps to chromosome 2. J Biol Chem 1994, 269:13092-13099.
24. Shimada T., Fujii-Kuriyama Y. Metabolic activation of polycyclic aromatic hydrocarbons to carcinogens by cytochromes P450 1A1 and 1B1. Cancer Sci 2004, 95:1-6.
25. Distlerath L.M., Reilly P.E., Martin M.V., Davis G.G., Wilkinson G.R., Guengerich F.P. Purification and characterization of the human liver cytochromes P-450 involved in debrisoquine 4-hydroxylation and phenacetin O-deethylation, two prototypes for genetic polymorphism in oxidative drug metabolism. J Biol Chem 1985, 260:9057-9067.
26. Tassaneeyakul W., Birkett D.J., Veronese M.E., McManus M.E., Tukey R.H., Quattrochi L.C., et al. Specificity of substrate and inhibitor probes for human cytochromes P450 1A1 and 1A2. J Pharmacol Exp Ther 1993, 265:401-407.
27. Sarkar M.A., Hunt C., Guzelian P.S., Karnes H.T. Characterization of human liver cytochromes P-450 involved in theophylline metabolism. Drug Metab Dispos 1992, 20:31-37.
28. Tjia J.F., Colbert J., Back D.J. Theophylline metabolism in human liver microsomes: inhibition studies. J Pharmacol Exp Ther 1996, 276:912-917.
29. Shimada T., Gillam E.M., Sutter T.R., Strickland P.T., Guengerich F.P., Yamazaki H. Oxidation of xenobiotics by recombinant human cytochrome P450 1B1. Drug Metab Dispos 1997, 25:617-622.
30. Nakamura H., Ariyoshi N., Okada K., Nakasa H., Nakazawa K., Kitada M. CYP1A1 is a major enzyme responsible for the metabolism of granisetron in human liver microsomes. Curr Drug Metab 2005, 6:469-480.
31. Reid J.M., Kuffel M.J., Miller J.K., Rios R., Ames M.M. Metabolic activation of dacarbazine by human cytochromes P450: the role of CYP1A1, CYP1A2, and CYP2E1. Clin Cancer Res 1999, 5:2192-2197.
32. Shet M.S., McPhaul M., Fisher C.W., Stallings N.R., Estabrook R.W. Metabolism of the antiandrogenic drug (Flutamide) by human CYP1A2. Drug Metab Dispos 1997, 25:1298-1303.
33. Rochat B., Morsman J.M., Murray G.I., Figg W.D., McLeod H.L. Human CYP1B1 and anticancer agent metabolism: mechanism for tumor-specific drug inactivation?. J Pharmacol Exp Ther 2001, 296:537-541.
34. Aramaki H., Tomiyasu N., Yoshimura H., Tsukamoto H. Forensic chemical study on marihuana. I. A detection method of the principal constituents by thin-layer and gas chromatographies. Chem Pharm Bull (Tokyo) 1968, 16:822-826.
35. Ono S., Hatanaka T., Hotta H., Satoh T., Gonzalez F.J., Tsutsui M. Specificity of substrate and inhibitor probes for cytochrome P450s: evaluation of in vitro metabolism using cDNA-expressed human P450s and human liver microsomes. Xenobiotica 1996, 26:681-693.
36. Huestis M.A., Henningfield J.E., Cone E.J. Blood cannabinoids. I. Absorption of THC and formation of 11-OH-THC and THCCOOH during and after smoking marijuana. J Anal Toxicol 1992, 16:276-282.
37. Ohlsson A., Lindgren J.E., Andersson S., Agurell S., Gillespie H., Hollister L.E. Single dose kinetics of cannabidiol in man. The cannabinoids: chemical, pharmacologic, and therapeutic aspects 1984, 219-225. Academic Press, New York. S. Agurell, W.L. Dewey, R. Willette (Eds.).
38. Johansson E., Ohlsson A., Lindgren J.E., Agurell S., Gillespie H., Hollister L.E. Single-dose kinetics of deuterium-labelled cannabinol in man after intravenous administration and smoking. Biomed Environ Mass Spectrom 1987, 14:495-499.
39. Marinol® package insert. http://www.marinol.com/.
40. Sativex® product monograph. http://www.bayerhealth.ca/.
41. Leighty E.G. Metabolism and distribution of cannabinoids in rats after different methods of administration. Biochem Pharmacol 1973, 22:1613-1621.
42. Fernandes M., Warning N., Christ W., Hill R. Interactions of several cannabinoids with the hepatic drug metabolizing system. Biochem Pharmacol 1973, 22:2981-2987.
43. Funahashi T., Ikeuchi H., Yamaori S., Kimura T., Yamamoto I., Watanabe K. In vitro inhibitory effects of cannabinoids on progesterone 17α-hydroxylase activity in rat testis microsomes. J Health Sci 2005, 51:369-375.
44. Chun Y.J., Kim S., Kim D., Lee S.K., Guengerich F.P. A new selective and potent inhibitor of human cytochrome P450 1B1 and its application to antimutagenesis. Cancer Res 2001, 61:8164-8170.
45. Chun Y.J., Ryu S.Y., Jeong T.C., Kim M.Y. Mechanism-based inhibition of human cytochrome P450 1A1 by rhapontigenin. Drug Metab Dispos 2001, 29:389-393.
46. Pastrakuljic A., Tang B.K., Roberts E.A., Kalow W. Distinction of CYP1A1 and CYP1A2 activity by selective inhibition using fluvoxamine and isosafrole. Biochem Pharmacol 1997, 53:531-538.
47. Chang T.K., Chen J., Yeung E.Y. Effect of Ginkgo biloba extract on procarcinogen-bioactivating human CYP1 enzymes: identification of isorhamnetin, kaempferol, and quercetin as potent inhibitors of CYP1B1. Toxicol Appl Pharmacol 2006, 213:18-26.
48. Bornheim L.M., Everhart E.T., Li J., Correia M.A. Characterization of cannabidiol-mediated cytochrome P450 inactivation. Biochem Pharmacol 1993, 45:1323-1331.
49. Bornheim L.M. Effects of unsaturated side-chain analogs of tetrahydrocannabinol on cytochromes P450. Biochem Pharmacol 2000, 60:955-961.
50. Bornheim L.M., Grillo M.P. Characterization of cytochrome P450 3A inactivation by cannabidiol: possible involvement of cannabidiol-hydroxyquinone as a P450 inactivator. Chem Res Toxicol 1998, 11:1209-1216.
51. Tassaneeyakul W., Birkett D.J., Veronese M.E., McManus M.E., Tukey R.H., Miners J.O. Direct characterization of the selectivity of furafylline as an inhibitor of human cytochromes P450 1A1 and 1A2. Pharmacogenetics 1994, 4:281-284.
52. Langouët S., Furge L.L., Kerriguy N., Nakamura K., Guillouzo A., Guengerich F.P. Inhibition of human cytochrome P450 enzymes by 1,2-dithiole-3-thione, oltipraz and its derivatives, and sulforaphane. Chem Res Toxicol 2000, 13:245-252.
53. Shimada T., Murayama N., Okada K., Funae Y., Yamazaki H., Guengerich F.P. Different mechanisms for inhibition of human cytochromes P450 1A1, 1A2, and 1B1 by polycyclic aromatic inhibitors. Chem Res Toxicol 2007, 20:489-496.
54. Chang T.K., Chen J., Lee W.B. Differential inhibition and inactivation of human CYP1 enzymes by trans-resveratrol: evidence for mechanism-based inactivation of CYP1A2. J Pharmacol Exp Ther 2001, 299:874-882.